The development and application of emerging technologies of Industry 4.0 enable the
realization of digital twins (DT), which facilitates the transformation of the manufacturing …

There is a trend across the pharmaceutical sector toward process intensification and
continuous manufacturing to produce small-molecule drugs or biotechnology products. For …

Process analytical technology (PAT) for the manufacture of monoclonal antibodies (mAbs) is
defined by an integrated set of advanced and automated methods that analyze the …

Rapid advances in intensifying upstream processes for biologics production have left
downstream processing as a bottleneck in the manufacturing scheme. Biomanufacturers are …

Highlights•Multiple companies are authorized to treat COVID-19 patients with monoclonal
antibodies (mAbs).•They were discovered, developed, manufactured, tested, and approved …

Pandemics and epidemics are continually challenging human beings' health and imposing
major stresses on the societies particularly over the last few decades, when their frequency …

Today's biologics manufacturing practices incur high costs to the drug makers, which can
contribute to high prices for patients. Timely investment in the development and …

Integrated continuous manufacturing is entering the biopharmaceutical industry. The main
drivers range from improved economics, manufacturing flexibility, and more consistent …

The changing landscape of the biopharmaceutical market is driving a paradigm shift toward
continuous manufacturing. To date, integrated continuous bioprocessing has not been …

There is a growing application of integrated and continuous bioprocessing (ICB) for
manufacturing recombinant protein therapeutics produced from mammalian cells. At first …